| Added by | pcoopman |
|---|---|
| Group name | EquipePC |
| Item Type | Journal Article |
| Title | Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations |
| Creator | Quesada et al. |
| Author | Stanislas Quesada |
| Author | Michel Fabbro |
| Author | Jérôme Solassol |
| Abstract | High-grade serous ovarian cancer (HGSOC), the most frequent and lethal form of ovarian cancer, exhibits homologous recombination deficiency (HRD) in 50% of cases. In addition to mutations in BRCA1 and BRCA2, which are the best known thus far, defects can also be caused by diverse alterations to homologous recombination-related genes or epigenetic patterns. HRD leads to genomic instability (genomic scars) and is associated with PARP inhibitor (PARPi) sensitivity. HRD is currently assessed through BRCA1/2 analysis, which produces a genomic instability score (GIS). However, despite substantial clinical achievements, FDA-approved companion diagnostics (CDx) based on GISs have important limitations. Indeed, despite the use of GIS in clinical practice, the relevance of such assays remains controversial. Although international guidelines include companion diagnostics as part of HGSOC frontline management, they also underscore the need for more powerful and alternative approaches for assessing patient eligibility to PARP inhibitors. In these companion reviews, we review and present evidence to date regarding HRD definitions, achievements and limitations in HGSOC. Part 1 is dedicated to technical considerations and proposed perspectives that could lead to a more comprehensive and dynamic assessment of HR, while Part 2 provides a more integrated approach for clinicians. |
| Publication | Cancers |
| Volume | 14 |
| Issue | 5 |
| Pages | 1132 |
| Date | 2022-02-23 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers14051132 |
| ISSN | 2072-6694 |
| Short Title | Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1 |
| Library Catalog | PubMed |
| Extra | PMID: 35267439 PMCID: PMC8909526 |
| Tags | BRCA, clinic, first-last-corresponding, genomic scars, high-grade serous ovarian cancer, HRD assays, PARP inhibitors |
| Date Added | 2022/07/29 - 18:18:25 |
| Date Modified | 2023/11/20 - 16:55:17 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
